Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate
AuthorsKrogstad, Paul A.
Gersten, Merril J.
Spector, Stephen A.
Bryson, Yvonne J.
UMass Chan AffiliationsDepartment of Pediatrics
Document TypeJournal Article
CD4 Lymphocyte Count
Drug Therapy, Combination
HIV Protease Inhibitors
Reverse Transcriptase Inhibitors
Immunology and Infectious Disease
MetadataShow full item record
AbstractAn open-label study was conducted of nelfinavir mesylate, given with reverse transcriptase inhibitors to human immunodeficiency virus 1 (HIV-1)-infected infants and children 3 months to 13 years of age. Doses of nelfinavir mesylate of 20-30 mg/kg yielded drug exposures comparable to those seen in adults. The drug was well tolerated; mild diarrhea was the primary toxic effect observed. Seventy-one percent (39) of the 55 evaluable subjects had an initial decrease in plasma HIV-1 RNA, of at least 0.7 log10 copies/mL; suppression of plasma HIV-1 RNA levels to < 400 copies/mL was observed in 15. Children who began taking at least one new reverse transcriptase inhibitor near the time when nelfinavir mesylate was started, and those with a > or = 24% proportion of CD4 lymphocytes, had a greater chance of achieving and maintaining a decline in plasma HIV-1 RNA to < 400 copies/mL. Suppression of viremia was achieved in children as young as 3 months of age.
SourceClin Infect Dis. 1999 May;28(5):1109-18. Link to article on publisher's site
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/43468
Related ResourcesLink to Article in PubMed